Geneyx Inc. a pioneering global company for an AI Multi-Omics analysis system, and [Pittsburgh, PA] Ocean Genomics, a leader in AI-ready Multi-Omics data, are pleased to announce the release of SVDuo™, an innovative software now available on Geneyx Analysis for research and clinical application and integrated into Ocean’s TxomeAI®. This advancement combines DNA and RNA analysis to enhance the detection of genomic variants, advancing disease diagnosis and the discovery of biomarkers and drug targets.
“The ability to accurately detect structural variants by integrating DNA and RNA analysis is transformative,” said Dr. Ayesha N. Shajahan-Haq, Assistant Professor of Oncology, at Georgetown University’s Lombardi Comprehensive Cancer Center. “SVDuo™ reveals previously undetectable variants, offering new insights into disease mechanisms and potential therapeutic targets.”
Carl Kingsford, CEO of Ocean Genomics, added, “Multi-Omics assays are essential for a deeper understanding of biological systems. Embedding SVDuo™ into our TxomeAI® platform empowers researchers to leverage multiple data modalities, identifying variants with great precision and potential as biomarkers and drug targets. We are grateful for the BIRD Foundation’s support in realizing this breakthrough.”
David Yizhar, CEO of Geneyx, emphasized, “Integrating SVDuo™ into Geneyx Analysis enhances our ability to deliver comprehensive genomic insights for clinical applications, improving diagnostic yield which benefits patients worldwide.”
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!